Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Babak Basiri"'
Autor:
Babak Basiri, Fang Xie, Bin Wu, Sara C. Humphreys, Julie M. Lade, Mai B. Thayer, Pam Yamaguchi, Monica Florio, Brooke M. Rock
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 21, Iss , Pp 725-736 (2020)
There has been a renewed interest in therapeutic small interfering RNAs (siRNAs) over the past few years. This is particularly the result of successful and efficient delivery of N-acetylgalactosamine (GalNAc)-conjugated siRNAs to the liver. In genera
Externí odkaz:
https://doaj.org/article/31612adf3dbc4f6d9346df118252c413
Autor:
Jaeah Kim, Babak Basiri, Chopie Hassan, Carine Punt, Erik van der Hage, Cathaline den Besten, Michael G. Bartlett
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 17, Iss , Pp 714-725 (2019)
Eluforsen (previously known as QR-010) is a 33-mer 2′-O-methyl modified phosphorothioate antisense oligonucleotide targeting the F508del mutation in the gene encoding CFTR protein of cystic fibrosis patients. In this study, eluforsen was incubated
Externí odkaz:
https://doaj.org/article/4ad7844a854e4018907780de4b1419c9
Publikováno v:
Methods in molecular biology (Clifton, N.J.). 2342
Therapeutic siRNA is a prodrug that requires Ago2-mediated site-specific hydrolysis of the sense strand before RNA interference can occur. Although this metabolic activation step was first described 15 years ago, the kinetics of this reaction, and it
Autor:
Cathaline den Besten, Erik R.E. van der Hage, Michael G. Bartlett, Babak Basiri, Chopie Hassan, Carine Punt, Jaeah Kim
Publikováno v:
Molecular Therapy. Nucleic Acids
Molecular Therapy: Nucleic Acids, Vol 17, Iss, Pp 714-725 (2019)
Molecular Therapy: Nucleic Acids, Vol 17, Iss, Pp 714-725 (2019)
Eluforsen (previously known as QR-010) is a 33-mer 2′-O-methyl modified phosphorothioate antisense oligonucleotide targeting the F508del mutation in the gene encoding CFTR protein of cystic fibrosis patients. In this study, eluforsen was incubated
Autor:
Sara C. Humphreys, Brooke M. Rock, Kelvin K. C. Sham, Richard Smith, Xin Huang, Bin Wu, Yue Hao, Babak Basiri, Mai B. Thayer, Julie M. Lade
Publikováno v:
Drug Metabolism and Disposition. 47:1174-1182
Understanding small interfering RNA (siRNA) fraction unbound (fu) in relevant physiologic compartments is critical for establishing pharmacokinetic-pharmacodynamic relationships for this emerging modality. In our attempts to isolate the equilibrium f
Publikováno v:
Sample Preparation in LC-MS Bioanalysis
Autor:
Mandi M. Murph, Shirin Hooshfar, J. Michael Sutton, Michael G. Bartlett, Babak Basiri, Charnel C. Byrnes
Publikováno v:
Journal of Chromatography A. 1584:97-105
In recent years, small endogenous RNAs have come to the forefront of both basic and translational research. For example, many studies have pointed to the potential role of microRNAs (miRNAs) as disease biomarkers. However, precise quantitative method
Publikováno v:
Methods in Molecular Biology ISBN: 9781071615539
Therapeutic siRNA is a prodrug that requires Ago2-mediated site-specific hydrolysis of the sense strand before RNA interference can occur. Although this metabolic activation step was first described 15 years ago, the kinetics of this reaction, and it
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a7d64f686c9c6119467e1fefa0b46f7f
https://doi.org/10.1007/978-1-0716-1554-6_31
https://doi.org/10.1007/978-1-0716-1554-6_31
Autor:
Pam Yamaguchi, Sara C. Humphreys, Mai B. Thayer, Bin Wu, Julie M. Lade, Fang Xie, Babak Basiri, Monica Florio, Brooke M. Rock
Publikováno v:
Molecular Therapy. Nucleic Acids
Molecular Therapy: Nucleic Acids, Vol 21, Iss, Pp 725-736 (2020)
Molecular Therapy: Nucleic Acids, Vol 21, Iss, Pp 725-736 (2020)
There has been a renewed interest in therapeutic small interfering RNAs (siRNAs) over the past few years. This is particularly the result of successful and efficient delivery of N-acetylgalactosamine (GalNAc)-conjugated siRNAs to the liver. In genera
Autor:
Noor S. Bala, Mai B. Thayer, Julie M. Lade, Omar S. Barnaby, Babak Basiri, Fang Xie, Brooke M. Rock, David R. Doherty
Publikováno v:
Scientific Reports
Scientific Reports, Vol 9, Iss 1, Pp 1-9 (2019)
Scientific Reports, Vol 9, Iss 1, Pp 1-9 (2019)
Despite the exquisite potential of siRNA as a therapeutic, the mechanism(s) responsible for the robust indirect exposure-response relationships have not been fully elucidated. To understand the siRNA properties linked to potent activity, requires the